What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “D-1553 is a oral dosed novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation”In the company’s words, NCT05379946 on ClinicalTrials.gov
- Tested for
- Solid Tumor
- Main trialPhase 1/2
- “This is a phase 1/2, open label study of D-1553 in combination with IN10018 to assess the safety and tolerability, identify the MTD and RP2D, evaluate the PK properties and antitumor activities in subjects with advanced or metastatic solid tumor with KRasG12C mutation”In the company’s words, NCT05379946 on ClinicalTrials.gov
- Other names
- other
Other drugs for Solid Tumor
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up1
- 31 Dec 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | 31 Dec 2027 | Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors | |
| Phase 1/2Completed | 17 Nov 2023 | Study to Evaluate D-1553 in Subjects With Lung Cancer | |
| Phase 1/2Unknown | 30 Apr 2024 | Study to Evaluate D-1553 in Subjects With Solid Tumors | |
| Phase 1/2Terminated | 14 Jun 2024 | A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer | |
| Phase 1Completed | 3 Jan 2024 | Mass Balance Study of [14C] D-1553 in Chinese Healthy Adult Male Subjects | |
| Phase 1Completed | 2 Feb 2024 | A Study to Evaluate the Effects of D-1553 on PK of Midazolam, Caffeine, Rosuvastatin, Furosemide, Digoxin, and Itraconazole or Omeprazole on PK of D-1553 |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026